IRVINE, Calif., June 26, 2023 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that it has been added to the broad-market Russell 3000® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after… Continue reading Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices
IRVINE, Calif., June 15, 2023 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company will present four posters at the 2023 Mitochondrial Medicine Symposium. The event, which is hosted by the United Mitochondrial… Continue reading Reneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023
IRVINE, Calif., May 31, 2023 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate at the Jefferies Healthcare Conference. Jefferies Healthcare ConferenceDate: Wednesday, June 7, 2023Location: Marriott Marquis, New… Continue reading Update — Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference
IRVINE, Calif., May 31, 2023 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate at the Jefferies Healthcare Conference. Jefferies Healthcare ConferenceDate: Wednesday, June 7, 2023Location: Lotte New York… Continue reading Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference
Completed enrollment of the pivotal STRIDE study; topline results anticipated 4Q 2023 Raised $68.3 million in gross proceeds from a concurrent public offering and private placement IRVINE, Calif., May 11, 2023 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial… Continue reading Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results
IRVINE, Calif., May 03, 2023 — Reneo Pharmaceuticals, Inc. (Reneo) (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced the pricing of its previously announced underwritten public offering of 6,875,000 shares of its common stock at a public offering price of… Continue reading Reneo Announces Pricing of Public Offering of Common Stock
IRVINE, Calif., May 03, 2023 — Reneo Pharmaceuticals, Inc. (Reneo) (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that it has commenced an underwritten public offering of its shares of common stock. Reneo intends to grant the underwriters a 30-day… Continue reading Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock
IRVINE, Calif., March 27, 2023 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter and year ended December 31, 2022 and provided a business update. 2022 and Recent Highlights Achieved the target… Continue reading Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Topline data from the STRIDE study expected in the fourth quarter of 2023 IRVINE, Calif., March 14, 2023 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company has achieved the target enrollment in the… Continue reading Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies
IRVINE, Calif., March 09, 2023 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company will present a preclinical poster at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting, being held in Salt Lake… Continue reading Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023